Announcements Trials
Browse Landscape

Phase

Phase 1 22Phase 2 20Phase 1/2 20Phase 3 8Phase NA 4Phase 4 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 14INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Neoplasms 66Breast Neoplasms 64Prostatic Neoplasms 46Carcinoma, Non-Small-Cell Lung 40Neoplasm Metastasis 23Colorectal Neoplasms 21Multiple Myeloma 20Pain 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Anemia 16Keratosis, Actinic 15Lung Neoplasms 14Cancer Pain 14Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 11Leukemia 11Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 9Carcinoma 9Neuroendocrine Tumors 8Melanoma 8Lymphoma 8Ovarian Neoplasms 7Leukemia, Myeloid, Acute 7Uterine Cervical Neoplasms 6Recurrence 6Gastrointestinal Stromal Tumors 6Stomatitis 5Stomach Neoplasms 5

Interventions

vandetanib 1lenvatinib 1cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Thyroid Neoplasms × Clear all
NCT03573960 2026-03-06

A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Eisai Inc.

Phase 4 Completed
50 enrolled
Head & Neck

Thyroid Neoplasms

NCT01496313 2025-10-03

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Sanofi

Phase 4 Completed
81 enrolled 15 charts
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms, Carcinoma, Medullary

NCT01896479 2025-09-02

EXAMINER

Exelixis

Phase 4 Active not recruiting
247 enrolled 14 charts
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡